Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · Real-Time Price · USD

13.04

-0.03 (-0.23%)

Feb 21, 2025, 4:00 PM EST - Market closed

Entrada Therapeutics Employees

Entrada Therapeutics had 159 employees as of December 31, 2023. The number of employees increased by 29 or 22.31% compared to the previous year.

Employees

159

Change (1Y)

29

Growth (1Y)

22.31%

Revenue / Employee

$1,353,660

Profits / Employee

$345,604

Market Cap

461.69M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	159	29	22.31%
Dec 31, 2022	130	16	14.04%
Dec 31, 2021	114	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	122,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

TRDA News

3 days ago - Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside - Seeking Alpha
19 days ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - GlobeNewsWire
23 days ago - Azenta Announces the Election of Dipal Doshi to its Board of Directors - PRNewsWire
2 months ago - Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
4 months ago - Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - GlobeNewsWire
5 months ago - Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - GlobeNewsWire
5 months ago - āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors - Business Wire
6 months ago - Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program - GlobeNewsWire